Alyssa K Francis1, Francesca L Beaudoin2, Safiya S Naidjate3, Christine Berard-Collins4, Andrew R Zullo5. 1. School of Public Health, Brown University, Providence, RI. 2. Associate Professor of Emergency Medicine and Health Services, Policy, and Practice, The Alpert Medical School of Brown University, Providence, RI. 3. Clinical Pharmacist Specialist, Ambulatory Care, Lifespan Corporation, Rhode Island Hospital, Providence, RI. 4. Director, Department of Pharmacy, Rhode Island Hospital; Clinical Pharmacist Specialist, Ambulatory Care, Lifespan Corporation, Rhode Island Hospital, Providence, RI. 5. Assistant Professor of Health Services, Policy, and Practice and Epidemiology, School of Public Health, Brown University; Research Fellow, Center of Innovation in Long-Term Services and Supports, Providence Veterans Affairs Medical Center; Clinical Pharmacist Specialist, Department of Pharmacy, Rhode Island Hospital, Providence, RI.
Abstract
OBJECTIVE: To compare sustained virologic response 12 weeks post-treatment completion (SVR12) and patient characteristics for older versus younger patients with chronic hepatitis C virus infection (HCV) receiving direct-acting antiviral (DAA) agent therapy. METHODS: This retrospective cohort study included patients with chronic HCV who received DAA therapy, between 2015 and 2018, in the largest health system in Rhode Island (N=154). Patient characteristics, comorbid diagnoses, and SVR12 status were compared between older (aged ≥60 years) and younger (<60 years) adults using chi-squared tests. RESULTS: Overall, 94.1% (95% CI: 90.4-97.8) achieved SVR12; response rates were 91.8% (95% CI: 84.9-98.6) for older adults and 95.6% (95% CI: 91.5-99.8) for younger adults (p=0.51). CONCLUSIONS: Our findings refute the historical notion that older adults were a "difficult-to-treat" subpopulation for whom clinicians should expect less treatment success. This is no longer the case with DAA therapy.
OBJECTIVE: To compare sustained virologic response 12 weeks post-treatment completion (SVR12) and patient characteristics for older versus younger patients with chronic hepatitis C virus infection (HCV) receiving direct-acting antiviral (DAA) agent therapy. METHODS: This retrospective cohort study included patients with chronic HCV who received DAA therapy, between 2015 and 2018, in the largest health system in Rhode Island (N=154). Patient characteristics, comorbid diagnoses, and SVR12 status were compared between older (aged ≥60 years) and younger (<60 years) adults using chi-squared tests. RESULTS: Overall, 94.1% (95% CI: 90.4-97.8) achieved SVR12; response rates were 91.8% (95% CI: 84.9-98.6) for older adults and 95.6% (95% CI: 91.5-99.8) for younger adults (p=0.51). CONCLUSIONS: Our findings refute the historical notion that older adults were a "difficult-to-treat" subpopulation for whom clinicians should expect less treatment success. This is no longer the case with DAA therapy.
Authors: Megan G Hofmeister; Elizabeth M Rosenthal; Laurie K Barker; Eli S Rosenberg; Meredith A Barranco; Eric W Hall; Brian R Edlin; Jonathan Mermin; John W Ward; A Blythe Ryerson Journal: Hepatology Date: 2018-11-06 Impact factor: 17.425
Authors: Lauren A Beste; Steven L Leipertz; Pamela K Green; Jason A Dominitz; David Ross; George N Ioannou Journal: Gastroenterology Date: 2015-08-05 Impact factor: 22.682
Authors: J Vermehren; K-H Peiffer; C Welsch; G Grammatikos; M-W Welker; N Weiler; S Zeuzem; T M Welzel; C Sarrazin Journal: Aliment Pharmacol Ther Date: 2016-08-23 Impact factor: 8.171
Authors: Safiya S Naidjate; Andrew R Zullo; Ruth Dapaah-Afriyie; Michelle L Hersey; Brandon D L Marshall; Richelle Manalang Winkler; Christine Berard-Collins Journal: Am J Health Syst Pharm Date: 2019-05-02 Impact factor: 2.637
Authors: Marcello Tonelli; Natasha Wiebe; Martin Fortin; Bruce Guthrie; Brenda R Hemmelgarn; Matthew T James; Scott W Klarenbach; Richard Lewanczuk; Braden J Manns; Paul Ronksley; Peter Sargious; Sharon Straus; Hude Quan Journal: BMC Med Inform Decis Mak Date: 2015-04-17 Impact factor: 2.796
Authors: Christina Yek; Carolina de la Flor; John Marshall; Cindy Zoellner; Grace Thompson; Lisa Quirk; Christian Mayorga; Barbara J Turner; Amit G Singal; Mamta K Jain Journal: BMC Med Date: 2017-11-20 Impact factor: 8.775